Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for June, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- 3 Top-Ranked Consumer ETFs to Buy Now
- RTI: When Will We Finally See a Pullback?
- RTI: When is the Fed's "Taper Telegraph" Coming?
- Top Stocks with Big Potential Catch-Up Moves
- Roundtable Top Picks of the Week
- Anatomy of Success: Green Mountain Coffee
- The Mega-Rally Rolls On
- Biotechnology ETF Investing 101
- 3 Dividend Stocks at Reasonable Prices
- AWS 5/21: The Beginning of the End for QE
- PFP 5/21: Below the Surface
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/21/2013
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| SUMMER INFAN | SUMR | 7.83% |
| FEDERAL MOGU | FDML | 6.25% |
| NATUS MEDICA | BABY | 5.62% |
| RADIANT LOGI | RLGT | 5.31% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Express Scripts Holding Company’s ( ESRX - Analyst Report ) fourth quarter 2012 adjusted earnings of $1.05 per share were in-line with the Zacks Consensus Estimate, and increased 28.1% from the year-ago period. Higher revenues aided earnings in the fourth quarter of 2012.
On a reported basis (including special items), earnings grew 5.1% to 62 cents in the fourth quarter of 2012.
For 2012, revenues came in at $93.8 billion, up 103.4% from 2011, and beat the Zacks Consensus Estimate of $92.8 billion. Adjusted earnings in 2012 came in $3.74, up 25.9% from 2011 and ahead of the Zacks Consensus Estimate of $3.72.
Quarter in Detail
Revenues jumped 126.5% in the reported quarter to $27.4 billion. The massive jump was attributable to the expanded product portfolio at Express Scripts due to the acquisition of Medco Health Solutions in 2011. Revenues were roughly in line with the Zacks Consensus Estimate.
Adjusted gross profit jumped 160.0% to $2.3 billion in the reported quarter. Gross profit was boosted by the inclusion of results of the erstwhile Medco Health Solutions, which led to improved operating performance, increased generic utilization and realization of synergies. Adjusted selling, general and administrative expenses climbed 263.9% to $784.5 million.
Total adjusted claims at Express Scripts for the reported quarter came in at 410.8 million, up 111%.
Cash flow from operations came in at $2.6 billion, significantly up from $0.5 billion in the fourth quarter of 2011.
2013 Earnings Outlook
We note that Express Scripts successfully integrated operations of erstwhile Medco Health Solutions in 2012. Express Scripts expects adjusted earnings for 2013 in the range of $4.20–$4.30 per share, up 12% – 15% over 2012.
The pre-earnings Zacks Consensus Estimate stands at $4.19. Adjusted claims are expected to grow 5% – 7% from 1,395.7 million in 2012, just shy of the company’s guidance.
Currently, Express Scripts carries a Zacks Rank #3 (Hold). Right now Covance Inc ( CVD - Snapshot Report ) , Omnicare Inc. ( OCR - Snapshot Report ) and Parexel International Corporation ( PRXL - Snapshot Report ) look better placed with a Zacks Rank #2 (Buy).
Read the full reports :
Analyst Report on ESRX
Snapshot Report on OCR
Snapshot Report on CVD
Snapshot Report on PRXL